Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.76 |
| ▸ | ACHE | P22303 | 5/20 | 0.70 |
| ▸ | BACE1 | P56817 | 5/20 | 0.70 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243398 | 0.86 | PDE3A (1.00) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL5241625 | 0.82 | PDE3A (0.68) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL5243694 | 0.82 | PDE3A (0.68) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL5241619 | 0.82 | PDE3A (0.68) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL5241633 | 0.82 | PDE3A (0.68) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL5243679 | 0.82 | PDE3A (0.68) | PDE3AACHEBACE1PDE10APDE3B | |
| SCHEMBL11882354 | 0.82 | ACHE (0.88) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL7276406 | 0.81 | ENPP1 (0.73) | PDE3AACHEBACE1PDE10AENPP1 | |
| SCHEMBL4965743 | 0.81 | ENPP1 (0.70) | PDE3AACHEBACE1PDE10AENPP1 | |
| SCHEMBL5245236 | 0.81 | PDE10A (1.00) | PDE3AACHEBACE1PDE10AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | claimed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0871448-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | claimed |
| EP-0831831-A4 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0831831-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5721237-A | ADMINISTERING FOR THE SELECTIVE TREATMENT OF CELL GROWTH AND DIFFERENTIATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-24 | — | — | US | claimed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | claimed |
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1488792-A2 | Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | Aventis Pharmaceuticals Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-6645969-B1 | Antiproliferative, anticarcinogenic, and antiinflammatory agents; treatment of leukemia, psoriasis, bone disorders, and atherosclerosis | AVENTIS PHARMACEUTICALS INC. | 2003-11-11 | — | — | US | disclosed |
| CN-1100540-C | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | AVENTIS PHARMA INC (US) | 2003-02-05 | — | — | CN | disclosed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | CSF1R, CSF3R, FLT3 | PDE3A 1443/4885ACHE 4476/4885BACE1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.